PAveMenT phase Ib trial (NCT04360941) investigated palbociclib/ avelumab combination in patients with androgen receptor-positive (AR +) TNBC(n = 12) and ER + /HER2- advanced BC(n = 2) [36]. The gene discussed is ERBB2; the disease is breast cancer.